Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

BACKGROUND: With the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in literature, aHUS patients can be treated accord...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Main Authors: Bouwmeester, Romy N., Ter Avest, Mendy, Wijnsma, Kioa L., Duineveld, Caroline, ter Heine, Rob, Volokhina, Elena B., Van Den Heuvel, Lambertus P. W. J., Wetzels, Jack F. M., van de Kar, Nicole C. A. J.
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Immunology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843372/
https://ncbi.nlm.nih.gov/pubmed/33519821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.612706
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares